KR102031663B1 - Cosmetic composition and external composition comprising glucosyl withanolides for anti-inflammatory - Google Patents

Abstract

The present invention relates to an anti-inflammatory cosmetic composition or an anti-inflammatory skin external preparation containing glycated glycan withanolides as an active ingredient.
The anti-inflammatory cosmetic composition or anti-inflammatory skin external preparation according to the present invention exhibits excellent cyclooxygenase inhibition and inflammation inhibitory effect, and is very excellent in cytotoxicity and skin safety as compared to existing anti-inflammatory agents.

Description

Anti-inflammatory cosmetic composition or anti-inflammatory external composition for skin comprising glycated witanolide as an active ingredient {Cosmetic composition and external composition comprising glucosyl withanolides for anti-inflammatory}

The present invention relates to an anti-inflammatory cosmetic composition or an anti-inflammatory skin external preparation comprising glycated glycan withanolides as an active ingredient.

Cosmetics are products used to protect the skin and to beautify cleanliness, but if you look closely at the cosmetic composition, ingredients different from the purpose of protecting the skin are used as essential to the formation of the product. Examples include surfactants, preservatives, fragrances, sunscreens, pigments, and other ingredients used to impart other benefits or effects. These components are generally known to cause various side effects such as inflammation, rash or edema in the skin (Maibach, H. I., Contact Dermatitis, 6; (1980) 369-404). In addition, sebum components, sweat components, fatty acids, cosmetics, and alcohol in cosmetics may be decomposed into highly toxic substances by skin flora, which may be present on the skin, thereby causing skin inflammation. . In particular, the recent development of functional cosmetics, even if there are some side effects on the skin, various functional cosmetics including ingredients such as AHA (alpha hydrosic acid), retinol or arbutin are commercially available.

Materials used for anti-inflammatory purposes to date are nonsteroidal flufenamic acid, ibuprofen, benzydamine or indomethacin, and prednisolone and dexamethasone as steroids. (dexamethasone), and other allantoin, azene, hydrocortisone, licorice acid or derivatives thereof (β-glycileic acid or glycylacenic acid derivatives) are known to be effective in anti-inflammatory (Ministry of Finance Cosmetology, Namsan Party, p162, 1993). However, steroidal substances have most problems in terms of skin safety and their usage is limited (Kim Chang-jong, Pathology Psychology, Hallym Co., p61-69, 1988). In addition, indomethacin may not be used in cosmetics, and licorice acid or derivatives thereof may be difficult to stabilize or have poor solubility.

Accordingly, the present invention not only has an excellent anti-inflammatory effect, but also is safe for the skin, and is easy to be formulated as a cosmetic composition or an external preparation for skin, and to provide an anti-inflammatory cosmetic composition or an anti-inflammatory skin external preparation including the same.

As a means for solving the above problems, the present invention provides an anti-inflammatory cosmetic composition or an anti-inflammatory skin external preparation comprising glycosylated withanolides as an active ingredient.

The witanolide is known to have a sedative effect, a stress inhibitory effect, an antioxidant or an immune regulating effect of the human body. Meanwhile, the inventors of the present invention are glycosylated withanolides in which a sugar is bound to a witanolide backbone in the process of discovering an excellent anti-inflammatory effect, safe for the skin, and easily formulated into a cosmetic composition or an external preparation for skin. ) Has been found to be an ingredient that is excellent in anti-inflammatory effect, less specific odor and safer to the skin, and completed the present invention. Through the following examples, the inventors confirmed that the glycated witanolide according to the present invention has excellent cyclooxygenase inhibitory effect and anti-inflammatory effect (Examples 1 and 2). In addition, it was confirmed that the skin safety for the human body is very excellent (Examples 3 and 4).

Glycosylated withanolides according to the present invention may be prepared using a commercially available product or by a known method through separation, semisynthesis or synthesis from plants. The plant may be, but is not limited to, Winter cherries (Withania somnifera), Angel's trumpet (Dunalia australis), Datura, Peruvian (Nicandra), Physalis, or Rhizomes of Tacca chantrieri. have. In addition, but is not limited thereto, for example, the glycosylated withanolides (sitoindoside IX, cytoindoside X, Dunawithanines A, Dunnawi) Taninanan B, Baimantuoluosides A, Baimantuoluosides B, Baimantuoluosides C, Cantriolide A and Cantriola It may be at least one selected from the group consisting of Chantriolides B.

Glycosylated withanolides according to the present invention can be prepared using commercially available products or based on known methods. The preparation of glycosylated glucosyl withanolides can be varied within the scope apparent to those skilled in the art, and the present invention includes the scope thereof. For example, the present invention may be isolated or purified from the extract of the plant.

The extraction solvent used to extract glycosylated withanolides from plants may be, but is not limited to, a solvent selected from water, organic solvents or mixtures thereof. The organic solvent may be a polar solvent such as alcohol having 1 to 5 carbon atoms, ethyl acetate or acetone, and a nonpolar solvent such as ether, chloroform, benzene, hexane or dichloromethane; Or a mixed solvent thereof. For example, the alcohol having 1 to 5 carbon atoms may be selected from methanol, ethanol, propanol, butanol or isopropanol and the like.

In addition, the glycosylated withanolides (glucosyl withanolides) according to the present invention may be a fraction obtained by re-fractionation of the primary extract extracted using the extraction solvent using an extraction solvent having a different polarity. For example, the solvent with different polarities may be ether, benzene or hexane.

Two or more solvents may be used in the fractionation, and each solvent extract may be prepared using sequentially or mixed according to the polarity of the solvent, but is not limited thereto.

The prepared extract or the fraction obtained by performing the fractionation process can be separated or purified the active ingredient according to a conventional separation and purification method. Although not limited thereto, High Performance Liquid Chromatography (HPLC) may be used.

The glycosylated withanolides prepared by the above method may be in the form of salts. The salt may be an acid addition salt formed using an organic acid or an inorganic acid, and the organic acid may be, for example, formic acid, acetic acid, propionic acid, lactic acid, butyric acid, isobutyric acid, trifluoroacetic acid, malic acid, maleic acid, malonic acid, fumaric acid, and the like. , Succinic acid, succinic acid monoamide, glutamic acid, tartaic acid, oxalic acid, citric acid, glycolic acid, glucuronic acid, ascorbic acid, benzoic acid, phthalic acid, salicylic acid, anthranilic acid, dichloroacetic acid, aminooxy acetic acid, benzenesulfonic acid, p-toluenesulfonic acid and It may be at least one selected from the group consisting of methanesulfonic acid salts. The inorganic acid may be at least one selected from the group consisting of hydrochloric acid, bromic acid, sulfuric acid, phosphoric acid, nitric acid, carbonic acid, and boric acid salts. It may preferably be in the form of hydrochloride or acetate, more preferably in the form of hydrochloride.

In addition to the above, salts that can be additionally salted are gabar salt, gabapentin salt, pregabalin salt, nicotinate, adipate salt, hemimalonate, cysteine salt, acetylcysteine salt, methionine salt, arginine salt, lysine salt, ornithine salt or Aspartate.

In the present invention, "inflammation" refers to a phenomenon that occurs when a cell or tissue is damaged by any cause to minimize the response and to restore the damaged site to its original state, and to restore nerves, blood vessels, and lymphatic vessels. It is a collective name for causing humoral reactions and cellular reactions, resulting in pain, edema, redness, and fever. The disease caused by the inflammation may be at least one selected from the group consisting of various dermatitis, allergies, systemic lupus erythematosus, retinitis, gastritis, hepatitis, enteritis, pancreatitis and nephritis, the allergy is anaphylaxis, allergic rhinitis ( allergic rhinitis, asthma, allergic conjunctivitis, allergic dermatitis, atopic dermatitis, contact dermatitis, urticaria, insect allergy, food allergy and drug allergy.

The inflammation is caused by various biochemical phenomena in vivo, and in particular, cyclooxygenase (COX) and L-arginine (L-), enzymes involved in biosynthesis of prostaglandin from arachidonic acid. Nitric oxide synthase (NOS), an enzyme that produces nitric oxide (NO) from arginin, is known to play an important role in mediating the inflammatory response.

In the present invention, the term "prostaglandin (PG)" is a kind of bioactive hormone synthesized in the body, and has a function of regulating the inflammatory response. The prostaglandins are of three types, PG1, PG2 and PG3, PG1 and PG3 inhibit inflammation, and PG2 causes inflammation. The prostaglandins are biosynthesized using cyclooxygenase (Cyclooxygenase, COX) using arachidonic acid as a precursor.

As used herein, the term "cyclooxygenase (Cyclooxygenase, COX)" is an enzyme that catalyzes the first step of synthesizing prostaglandin, and introduces two molecules of oxygen into arachidonic acid to synthesize PG2, thereby producing prostaglandin endoperoxide. Also called synthase. Cyclooxygenase (COX) also has two types of isoforms. Cyclooxygenase-1 (COX-1) is always present in cells to provide prostaglandins (PGs) necessary for cytoprotective action. While synthesizing, COX-2 is known to play an important role in the inflammatory response due to a rapid increase in cells during the inflammatory response.

The term "nitric oxide (NO)" in the present invention is generated by iNOS (induced NOS) induced by various cytokines or external stimuli, and is known to cause cytotoxicity or various inflammatory reactions. In addition, chronic inflammation is known to be associated with increased iNOS activity (Appleton L. et al Adv. Phamacol., 35. 27-28.1996).

The glycated witanolide according to the present invention has a cyclooxygenase (COX) inhibitory activity, and is particularly effective for inflammation mediated by biosynthesis of prostaglandins.

The present invention can provide a desirable anti-inflammatory effect when including an effective amount of glycated witanolide. In the present invention, "effective amount" means an amount capable of exhibiting sufficient cyclooxygenase (COX) inhibitory activity. For example, the effective amount of the glycated witanolide included in the anti-inflammatory composition of the present invention may be included in an amount of 0.001 to 20 parts by weight based on 100 parts by weight of the total composition. For example, it may be 0.001 to 10 parts by weight, 0.01 to 20 parts by weight, 0.01 to 10 parts by weight and 0.1 to 10 parts by weight. This may not be expected to have sufficient anti-inflammatory effects when the glycated witanolide is included in less than 0.001 part by weight, and when it contains more than 20 parts by weight, an unwanted reaction such as allergy may occur or there may be a problem in skin safety. This is to prevent this. The composition as described above is not necessarily limited thereto, and may vary depending on the purpose of the composition, the form to be commercialized, and the state of the application target.

On the other hand, the composition of this invention may contain 1 or more types of components which show a well-known anti-inflammatory effect, and a component which enhances an anti-inflammatory effect.

By including additional anti-inflammatory components, the anti-inflammatory effect may be further enhanced. As anti-inflammatory ingredients known in the art, ibuprofen, flufenamic acid and indomethacin on the nonsteroidal side, prednisolone and dexamethasone on the steroid side, other allantoins, azene It may further comprise one or two or more components selected from the group consisting of hydrocortisone, licorice acid and derivatives thereof. The additional anti-inflammatory component includes all the analogs and the like having the same effects as those listed above. In addition, as a known anti-inflammatory component that can be used in cosmetic compositions, hyaluronic acid, Daphnetin, glycyrrhizin, quercetin, rosmarinic acid, madecassic acid , Camazulene, Bicalein, Emodin, Astaxanthin, norbergenin, 4-O-methylhonokiol, Polydatin (polydatin), ferulic acid, 2-methoxycinnamaldehyde, 2,4-dihydroxyacetophenone, terpinen-4-ol (terpinen-4) -ol) and one or more components selected from the group consisting of derivatives thereof. The additional anti-inflammatory components may include all of the analogues and plant extracts thereof having the same effect as those listed above.

The added ingredients may be included in 0.0001 to 10 parts by weight with respect to 100 parts by weight of the total composition, the content range according to the requirements of the activity of cyclooxygenase (Cyclooxygenase, COX), skin safety, ease of formulation, etc. It can be adjusted.

The cosmetic composition or the external preparation for skin according to the present invention may be formulated through conventional methods. When formulated as an external preparation for skin, reference may be made to what is disclosed in Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA, and when formulated as a cosmetic, International cosmetic ingredient dictionary, 6th ed., The cosmetic, Toiletry and Fragrance Reference may be made to the contents disclosed in Association, Inc., Washington, 1995. Such documents are incorporated as part of this specification.

Although not limited thereto, the cosmetic composition may be prepared in the form of a general emulsion formulation and solubilized formulation. For example, lotion, such as a flexible lotion or a nourishing lotion; Latex, such as facial lotion or body lotion; Creams such as nutrition creams, moisture creams or eye creams; essence; Cosmetic ointments; spray; Gels; pack; Sunscreen; Makeup base; Foundations such as liquid type, solid type or spray type; powder; Makeup removers such as cleansing creams, cleansing lotions or cleansing oils; Or formulations of detergents such as cleansing foams, soaps or body washes. In addition, the external preparation for the skin may have a formulation such as, but not limited to, ointment, patch, gel, cream or spray.

The content of the active ingredient may vary depending on the formulation. For example, the cosmetic composition may include a relatively high concentration of the glycated witanolide in the case of a wash-off type cosmetic such as a makeup remover or a detergent, in which an active ingredient stays on the skin within a short period of time. will be. On the other hand, in the case of leave-on cosmetics such as lotion, emulsion, cream, essence, etc., in which the active ingredient stays on the skin for a long period of time, a lower concentration of glycated witanolide than the wash-off cosmetics is used. It may be included.

In addition, it may further include adjuvants or carriers such as stabilizers, solubilizers, vitamins, pigments, or flavors that are commonly used in cosmetic compositions or external preparations for skin. For example, fatty substances, organic solvents, solubilizers, thickeners, gelling agents, softeners, antioxidants, suspending agents, stabilizers, foaming agents, fragrances, surfactants, water, ionic emulsifiers, nonionic emulsifiers, fillers , Metal ion sequestrants, chelating agents, preservatives, vitamins, blockers, wetting agents, essential oils, dyes, pigments, hydrophilic active agents, lipophilic active agents, lipid vesicles, cosmetics or any other ingredients commonly used in external preparations for skin It may contain adjuvants conventionally used in the field of cosmetics or dermatology. The ingredients may also be introduced in amounts generally used in the cosmetic or dermatological fields.

Glycosylated withanolides according to the present invention exhibited excellent cyclooxygenase (COX) inhibition and inflammation inhibitory effect, and was very excellent in cytotoxicity and skin safety compared to conventional anti-inflammatory agents.

Advantages and features of the present invention, and methods for achieving them will be apparent with reference to examples and preparations described below in detail. However, the present invention is not limited to the examples and preparations disclosed below, but will be implemented in various different forms, only to make the disclosure of the present invention complete, and having ordinary skill in the art to which the present invention pertains. It is provided to inform the full scope of the invention.

Example 1

Inhibitory effect of cyclooxygenase (Cyclooxygenase, COX)

In the present invention, cyclooxygenase (Cyclooxygenase, COX) was extracted from Pel-Freeze's sheep seminal vesicle (sheep seminal vesicle) was used. Cyclooxygenase according to the present invention (Cyclooxygenase, COX) is the supernatant is taken by centrifugation for 10 minutes at 3000rpm after pulverizing the two hyposperm, the supernatant is centrifuged for 1 hour at 10000rpm to separate the precipitate and Tris buffer It was prepared by dissolving in (0.1M, pH 8.0).

25 μg hemoglobin is added to 100 mL of Tris buffer solution (0.1M, pH 8.0) to make a substrate to 1.1 mM arachidonic acid, and then 10 μl of 10,000 units of cyclooxygenase is added to the substrate. Cytoinside IX, Cytoinside X, and Dunanawitannin A were added to each of 0.5 ppm, 10 ppm, and 50 ppm, respectively, and then the initial oxygen consumption was measured using a Yellow Spring Instrument company. Seegenase activity was confirmed. The results are shown in Table 1 below.

% Inhibition 0.5 ppm 10 ppm 50 ppm (w / w) Cito Indian Side IX 21 ± 2 34 ± 3 48 ± 4 Cito Indiaside X 16 ± 3 30 ± 5 46 ± 2 Dunawitanin A 19 ± 2 35 ± 4 45 ± 5

n = 3

As can be seen in Table 1, when 50ppm, 45% of cytoindoside IX (50ppm), 46% of cytoindoside X (50ppm), and Dunanawitan A (50ppm) compared to the negative control for cyclooxygenase It was confirmed that the inhibitory effect of%.

Example 2

Anti-inflammatory effect test

A. Crummey, GP Harper, EA Boyle and FR Mangan.Inhibition of arachidonic acid-induced ear edema as a model for assessing topical anti-inflammatory compound.Agents and Actions 1987: 20: 69 -76) to determine the anti-inflammatory effect.

A total of 56 hairless mice were made of 7 dogs each and 8 sets were made. Both ears of the mouse were thoroughly washed with ethanol, and the thickness was measured using a micrometer. A sample group coated with samples containing 1 ppm and 10 ppm of cytotoside IX, cytotoside X and dunawittanin A, a comparative group coated with a sample containing 1 ppm of indomethacin, and a control group coated with ethanol Divided by.

Inflammation was induced by applying 2 mg / ear of arachidonic acid to the right ear of the mouse, and ethanol was applied to the left ear to determine the degree of inflammation caused by the sample itself. One hour later, the sample group contained 1 ppm and 10 ppm each of cytoinside IX, cytoinside X, and dunawittanin A on both ears coated with ethanol and arachidonic acid, respectively, and the comparison group was 1 ppm of indomethacin. The sample containing the control, ethanol was applied to both ears of the mouse continuously for 4 days at 20 μl once a day. After 1 hour of application, the degree of edema of both ears was measured three times for each ear using a micrometer. The edema inhibition rate of the sample for the control group (ethanol) is shown in Table 2, and the edema inhibition rate for the comparative group (indometacin) is shown in Table 3.

sample density Ear thickness (㎛) % Inhibition Before sample processing After sample processing Sample group Cito Indian Side IX 1 ppm 322 493 39.1 10 ppm 321 487 40.9 Cito Indiaside X 1 ppm 324 506 35.1 10 ppm 320 493 38.4 Dunawitanin A 1 ppm 319 493 37.8 10 ppm 324 488 41.6 Comparison Indomethacin 1.0 325 452 54.8 Control ethanol 2mg / ear 321 602 -

※ % Inhibition = (AB) / A × 100

   A: average thickness change of control ear

       (Thickness of arachidonic acid-treated ears-thickness of untreated ears)

   B: average thickness change of the sample coated group ears

(Thickness of sample treated ears-thickness of untreated ears)

% Inhibition compared to the control group (Indometacin) 1 ppm 10 ppm Cito Indian Side IX 71% 75% Cito Indian Side X 64% 70% Dunanawitannin A 69% 76%

As shown in Table 2, at 10 ppm, cytoindoside IX showed 40.9%, cytoindoside X showed 38.4%, and dunawittanin A showed high inflammation inhibition rate of 41.6%. In addition, as shown in Table 3, at 10 ppm, the cytosineside side IX compared to indomethacin was 75%, the cytosine side X was 70%, and dunnitanin A showed an excellent anti-inflammatory effect.

On the other hand, when the significant difference was verified by the increase rate of edema, cytoinside IX, cytoinside X, and dunawittanin A showed an effect of 99% difference with arachidonic acid.

Example 3

Human patch test for humans

Fifty healthy men and women were subjected to a primary stimulation test in humans according to CTFA guidelines (The Cosmetic, Toiletry and Fragrance Association. Inc. Washington, D.C., 20036, 1991).

50 ppm of cytoinside IX, cytoinside X or dunawittanin A, a sample containing 1.0% sodium lauryl sulphate and 10% ethanol, a sample containing 1.0% sodium lauryl sulphate and 10% ethanol, and Human irritation was evaluated using 10% ethanol as a sample. Each 20 µl of the samples was added dropwise to a Fin chamber, and it was placed on the back of the human body as a test site and fixed with tape. After patching for 24 hours, the patch was then removed. After removing the patch for 4 hours, the skin reaction at the test site was determined according to the following criteria, and the results are shown in Table 4.

    <Judge criteria>

      －: No erythema or unusual phenomenon

      ±: slightly reddish

      +: Significantly redder than the surroundings

    + +: Reddens and swells more heavily than the surroundings

Stimulus = [{(±) Number × 1} + {(+) Number × 2} + {(++) Number × 3}] / Number of Subjects

sample The number of the subjects Judgment result Irritation + + ± － Cytoindole IX (50 ppm), Sodium Lauryl Sulfate (1%), Ethanol (10%) 50 - - 4 46 0.08 Cytoindoside X (50 ppm), Sodium Lauryl
Sulfate (1%), Ethanol (10%) 50 - - 7 43 0.14 Dunawitanin A (50 ppm), Sodium Lauryl
Sulfate (1%), Ethanol (10%) 50 - - 4 46 0.08 Sodium lauryl sulfate (1%),
Ethanol (10%) 50 2 8 10 30 0.60 Ethanol (10%) 50 - - 10 40 0.20

As can be seen in Table 4, cytoinside IX, cytoinside X and dunawittanin A greatly alleviated the stimulation of sodium lauryl sulfate and ethanol. This result is thought to be due to the excellent anti-inflammatory effect as shown in the anti-inflammatory effect experiment described above, through which the cytoindoside IX, cytoindoside X or Dunawitanin A according to the present invention is a safe component to the skin Able to know.

Example 4

Anti-inflammatory sensory test on human body

Ten subjects of 50 ppm of cytoindoside IX, cytotoinside X, and dunawittanin A were patched twice a day for 7 days to observe the change. Water was used as a control.

Sample (50 ppm) Effective (persons) No change (persons) Cito Indian Side IX 7 3 Cito Indiaside X 8 2 Dunawitanin A 8 2 water 2 8

As can be seen in Table 5, cytoinside IX, cytoinside X, Dunawitanin A effectively alleviated the rash. This result is thought to be due to the excellent anti-inflammatory effect as shown in the anti-inflammatory effect experiment described above, through which the cytoindoside IX, cytoindoside X and Dunawitanin A according to the present invention is a safe component to the skin Able to know.

Hereinafter, the preparation examples (formulation examples) of the cosmetic composition of the present invention are shown, but the following preparation examples are merely illustrative of the composition of the present invention, but are not limited thereto.

[Production Example 1]

toilet water

Raw material weight% (w / w)

Glycerin 5.0

Dipropylene Glycol 3.0

Hyaluronic Acid 0.5

Polyoxyethylene 0.1

Cured Castor Oil 0.1

Polyethylene Oleylethyl Ethanol 5.0

Preservative 0.15

Spices

Pigment amount

Compound 0.1 of Formula 1

Purified Water to 100

[Production Example 2]

essence

Raw material weight% (w / w)

Cetostearyl Alcohol 1.0

Self-Emulsifying Monostearic Acid 1.0

Beeswax 0.5

Squalane 5.0

Isocetyloctanoate 3.0

Dimethylsiloxane 0.3

Sorbitan monomonate 0.5

Monostearic acid polyethylene glycol 8.0

Glycerin 4.0

Propylene Glycol 0.2

Carboxypolymer 0.22

Triethanolamine 0.25

Preservative

Spices

Pigment amount

Compound of Formula 1 7.0

Purified Water to 100

[Production Example 3]

Lotion

Raw material weight% (w / w)

Cetostearyl Alcohol 0.8

Self-Emulsifying Monostearic Acid 10

Beeswax 0.5

Stearic Acid 0.5

Liquid Paraffin 7.0

Squalane 5.0

Macadamia Oil 3.0

Isocetyloctanoate 2.0

Dimethylsiloxane 0.3

Sorbitan monomonate 0.5

Monostearic acid polyethylene glycol 1.2

Glycerin 4.0

Propylene Glycol 4.0

Betaine 4.0

Carboxypolymer 0.12

Triethanolamine 0.15

Preservative 0.25

Spices

Pigment amount

Compound 5.0 of Formula 1

Purified Water to 100

[Production Example 4]

cream

Raw material weight% (w / w)

Cetostearyl Alcohol 3.0

Self-Emulsifying Monostearic Acid 1.5

Lipophilic Monostearic Acid 1.5

Beeswax 0.5

Liquid Paraffin 8.0

Squalane 7.0

Isocetyloctanoate 4.0

Refined Jojoba Oil 4.0

Dimethylsiloxane 0.3

Sorbitan monosulfate 1.0

Monostearic acid polyethylene glycol 1.2

Glycerin 6.0

Propylene Glycol 4.0

Betaine 4.0

Xanthan Gum 0.06

Triethanolamine 0.10

Preservative 0.25

Spices

Pigment amount

Compound of Formula 1 7.0

Purified Water to 100

Production Example 5

Gel

Raw material weight% (w / w)

Glycerin 4.0

Propylene Glycol 4.0

Ethanol 10

Polyoxyethylene Cured Castor Oil 0.1

Carboxy Polymer 0.30

Triethanolamine 0.30

Preservative

Spices

Pigment amount

Compound of Formula 1 1.0

Purified Water to 100

[Manufacture example 6]

Ointment

Raw material weight% (w / w)

Cetostearyl Alcohol 2.0

Self-Emulsifying Monostearic Acid 2.0

Stearic Acid 1.0

Beeswax 4.0

Squalane 7.0

Monostearineglycerin 3.0

Sorbitan monosulfate 1.0

Polysorbate 80 3.0

Glycerin 5.0

Propylene Glycol 4.0

Spices

Pigment amount

Compound 10.0 of Formula 1

Vaseline to 100

Claims (12)

Anti-inflammatory cosmetic composition comprising Dunawithanines A (Dunawithanines A) as an active ingredient.
The method of claim 1,
The Dunawithanines A (Dunawithanines A) is an anti-inflammatory cosmetic composition that is an extract obtained from plants or obtained through synthesis or semisynthesis.
The method of claim 2,
The plant is 1 selected from the group consisting of Withania somnifera, Angel's trumpet (Dunalia australis), Datura, Peruvian (Nicandra), Physalis and Rhizomes of Tacca chantrieri. Anti-inflammatory cosmetic composition of more than one species.
The method of claim 1,
The Dunawithanines A (Dunawithanines A) is an anti-inflammatory cosmetic composition comprising 0.001 to 20 parts by weight based on 100 parts by weight of the total cosmetic composition.
The method of claim 1,
The anti-inflammatory cosmetic composition is an anti-inflammatory cosmetic composition having a formulation selected from the group consisting of lotion, emulsion, cream, essence, spray, gel, pack, sunscreen, makeup base, foundation, powder and detergent.
Anti-inflammatory skin external preparation containing Dunawithanines A as an active ingredient.
The method of claim 6,
The Dunawithanines A (Dunawithanines A) is an anti-inflammatory skin external preparation that is obtained from an extract isolated from plants or synthetic or semisynthetic.
The method of claim 7, wherein
The plant is 1 selected from the group consisting of Withania somnifera, Angel's trumpet (Dunalia australis), Datura, Peruvian (Nicandra), Physalis and Rhizomes of Tacca chantrieri. Anti-inflammatory skin external preparations of more than one species.
The method of claim 6,
The Dunawithanines A (Dunawithanines A) is an anti-inflammatory skin external preparation comprising 0.001 to 20 parts by weight based on 100 parts by weight of the total composition.
The method of claim 6,
The skin external preparation is an anti-inflammatory skin external preparation having a formulation selected from the group consisting of ointments, patches, gels, creams or sprays.
delete delete